Background: This study compared the performance of plasma infliximab and adalimumab quantification using a commercially available kit (mAbXmise kit) and mass spectrometry readout to that of two ELI...
Background: Therapeutic drug monitoring of infliximab is commonly performed based on trough concentration. However, doses and dosing intervals may be adapted to patient outcomes, and this trough concentration target may correspond to a large range of exposures in terms of the area under the concentration–time curve (AUC). The objectives of this study were to assess the real-life exposure to intravenous infliximab in patients with Crohn disease in remission at year 1 and to assess the evolution of exposure in patients who switched to subcutaneous infliximab. Methods: The authors conducted a retrospective observational pharmacokinetic study in patients with Crohn disease who had available infliximab concentrations during intravenous and subcutaneous infliximab maintenance therapy as per the standard of care. Infliximab exposure parameters (AUCs and trough concentrations, C0) were compared for different dosing regimens of intravenous infliximab before (intravenous) and after (subcutaneous) the switch. Results: A total of 113 patients had 383 intravenous infliximab concentrations. Dosing intervals ranged from 4 to 12 weeks. The median/range/CV% C0, AUC0-t, and AUC0–8weeks were 5.3 mcg/mL [<LLoQ-49.6]/71.6%, 37,792 mcg.h/mL [4971–116,366]/33.1%, and 41,582 mcg.h/mL [7953–232,048]/43.9%, respectively. Forty-one patients had available paired C0 after both intravenous and subcutaneous administration. A poor correlation was found between preswitch intravenous infliximab C0 and postswitch subcutaneous infliximab C0. Conclusions: In this study, the authors suggested that in patients treated with IV IFX, different targets of C0 should be proposed according to treatment schemes and that AUC0-t might be a relevant determinant of clinical remission. Moreover, exposure did not remain stable throughout the switch from IV to SC IFX in any patient. These variations may depend on the intravenous dosing interval before switching.
12 August 2026 in CPT: Pharmacometrics & Systems Pharmacology
Selecting the most relevant models for model‐informed precision dosing (MIPD) remains challenging, particularly when numerous population pharmacokinetic (popPK) models are available, making external evaluation of all candidates time‐ and resource‐consuming. We aimed to develop and assess an adaptable relevance‐based scoring methodology, illustrated with tacrolimus in adult transplant recipients. Candidate criteria were derived from published guidelines and external evaluations. A 23‐item relevance score was developed, covering training dataset, study design, evaluation methodology, covariates, and parameter precision. For tacrolimus, a systematic literature review identified 28 models which were scored for relevance and externally evaluated using an independent dataset from Rennes University Hospital (86 patients). Predictive performances were assessed at individual and population levels using bias and imprecision metrics. Predicted and observed AUCs were compared against therapeutic thresholds. Models were then ranked using an external evaluation score (maximum 14 points) based on predefined acceptance limits for bias and imprecision. Correlations between relevance‐based and external scores and ranks were assessed using Pearson and Spearman correlations. The mean relevance score was 22.3/56 (range: 6–38). Higher scores were associated with larger and richer datasets, prospective or multicentric designs, inclusion of clinically relevant covariates, and precise parameter estimates. Individual predictions showed acceptable bias and imprecision, whereas population predictions were consistently inaccurate. AUC concordance (56%–94%) was mainly limited by overestimation. Highest external score was 6/14. Correlation between relevance‐based and external scores was moderate (Pearson = 0.56; Spearman = 0.61). This work provides a structured basis for popPK model selection and identified tacrolimus models suitable for MIPD applications.